Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate*

The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis

(2010) Margareta Blombäck et al.   THROMBOSIS AND HAEMOSTASIS

Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats

(2010) Susanne Pehrsson et al.   THROMBOSIS AND HAEMOSTASIS

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists

(2009) G. Y.H. Lip et al.   EUROPEAN HEART JOURNAL

Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty

(2009) Lars C Borris   EXPERT OPINION ON PHARMACOTHERAPY

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Parenteral Anticoagulants

(2008) Jack Hirsh et al.   CHEST

New Antithrombotic Drugs

(2008) Jeffrey I. Weitz et al.   CHEST

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

(2008) Jennifer Carreiro et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

New therapeutic option for thromboembolism – dabigatran etexilate

(2008) Hitoshi Nishio et al.   EXPERT OPINION ON PHARMACOTHERAPY